Experimental Gastric Non-Balloon Devices

Choi, Youn I; Kim, Kyoung Oh

doi:10.5946/ce.2018.150

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is a major public health concern globally and is linked to various metabolic and psychological problems, such as heart disease, stroke, diabetes, hypertension, and sleep disorders. − Endoscopic bariatric therapies, including intragastric balloons, endoscopic suturing devices, full sense devices, and bypass liners, have been developed as alternatives to bariatric surgery for high-risk obese patients and those who refuse surgery. − Recently, a new version named the intragastric satiety-inducing device (ISD) was developed and evaluated in rat and porcine models. − The ISD reduced food intake and suppressed weight gain with reduced ghrelin hormone levels . However, device-related esophagogastric reflux, a high risk of migration into the stomach, and device-induced reversible inflammatory reaction with tissue hyperplasia were reported. , Although antimigration designs (i.e., barbs, flaps, and antireflux valves) were applied, these device-related complications were still inevitable …”

Section: Introductionmentioning

confidence: 99%

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Lee

Kim

Park

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Bariatric surgery is the most effective treatment for weight recidivism, and endoscopic bariatric treatment has been developed for a similar effect without anatomical modification. An intragastric satiety-inducing device (ISD) is a minimally invasive approach to induce satiety by continuously pressing the stomach and stimulating ghrelin-producing cells. To enhance the therapeutic effects of ISD, photodynamic therapy (PDT) can be combined by generating singlet oxygen under laser irradiation. Methylene blue (MB), as a photosensitizer (PS), was coated on the ISD surface for singlet oxygen production to stimulate or destroy cells. Ghrelin-producing cells effectively inhibited ghrelin secretion and induced gastrointestinal satiety signals compared with the MB-uncoated device via PDT. Herein, MB-embedded ISDs were developed, and their photoresponsive abilities were demonstrated in the device itself and in vitro. PDT with an MB-embedded ISD was successfully performed in a porcine model, which had 2-fold reduced body weight gain (12% in PDT vs 24% in control) and 2-fold reduced ghrelin levels (21.2 pg/mL in PDT vs 45.1 pg/mL in control) at the first week postprocedure. The simple and unique operation extends the point of view in PDT and is expected to be a novel endoscopic bariatric therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Lee

Kim

Park

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…The range of EBT procedures is extensive, reflecting how serious the problem of obesity is. In our discussion, we benefit of a number of excellent reviews [147,148,149,150,151,152,153,154,155] covering the vast literature dedicated to the EBT techniques and devices. As compared to other devices routinely inserted in the GI tract, those specific to EBTs should be most exposed to biocompatibility-related effects.…”

Section: Biomaterials In Endoscopic Bariatric Therapiesmentioning

confidence: 99%

Biomaterials in Gastroenterology: A Critical Overview

Goldiş

Goldis²,

Chirilă

2019

Medicina

View full text Add to dashboard Cite

In spite of the large diversity of diagnostic and interventional devices associated with gastrointestinal endoscopic procedures, there is little information on the impact of the biomaterials (metals, polymers) contained in these devices upon body tissues and, indirectly, upon the treatment outcomes. Other biomaterials for gastroenterology, such as adhesives and certain hemostatic agents, have been investigated to a greater extent, but the information is fragmentary. Much of this situation is due to the paucity of details disclosed by the manufacturers of the devices. Moreover, for most of the applications in the gastrointestinal (GI) tract, there are no studies available on the biocompatibility of the device materials when in intimate contact with mucosae and other components of the GI tract. We have summarized the current situation with a focus on aspects of biomaterials and biocompatibility related to the device materials and other agents, with an emphasis on the GI endoscopic procedures. Procedures and devices used for the control of bleeding, for polypectomy, in bariatrics, and for stenting are discussed, particularly dwelling upon the biomaterial-related features of each application. There are indications that research is progressing steadily in this field, and the establishment of the subdiscipline of “gastroenterologic biomaterials” is not merely a remote projection. Upon the completion of this article, the gastroenterologist should be able to understand the nature of biomaterials and to achieve a suitable and beneficial perception of their significance in gastroenterology. Likewise, the biomaterialist should become aware of the specific tasks that the biomaterials must fulfil when placed within the GI tract, and regard such applications as both a challenge and an incentive for progressing the research in this field.

show abstract

“…while eliminating surgery-related complications and improving patient quality of life [5][6][7][8][9]. These alternative therapies include endoscopic bariatric therapies using intragastric balloons, endoscopic suturing devices, and bypass liners [10][11][12][13]; however, high costs, high risk of adverse events, and low patient acceptance are major concerns [14][15][16]. Because the fundus of the stomach is the major site for producing ghrelin (the hunger hormone), two types of self-expandable, metallic stent-based devices, i.e., full-sense devices and intragastric satiety-inducing devices (ISDs), inhibit ghrelin production by applying physical pressure on the fundus and cardia [17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Repeated photodynamic therapy using a chlorin e6‐embedded device to prolong the therapeutic effects on obesity

Park,

Kim,

Ryu

et al. 2024

Obesity

View full text Add to dashboard Cite

ObjectiveThis study aimed to investigate the efficacy and safety of repeated photodynamic therapy (PDT) with a chlorin e6 (Ce6)‐embedded intragastric satiety‐inducing device (ISD) to maintain therapeutic effects of obesity in a juvenile pig.MethodsThe Ce6‐embedded ISD was fabricated with a dipping method. Twelve pigs were divided into four groups of three and were administered control, single, biweekly, or weekly PDT, respectively. The therapeutic effects were assessed by comparing the results of phototoxicity, endoscopy, fluoroscopy, hormone and weight changes, and histological examination.ResultsThe percentage of total body weight gain was significantly suppressed in PDT‐treated pigs compared with control pigs (all p < 0.001). This suppression persisted in the repeated PDT groups, but percentage of total body weight gain gradually increased when PDT was stopped. Ghrelin levels in the PDT‐treated groups were significantly lower and leptin levels were significantly higher than those in the control group (all p < 0.05). Inflammatory cell infiltration, collagen, TUNEL, and anti‐ghrelin‐positive deposition in the weekly group were significantly higher than those in the control, single, and biweekly groups (all p < 0.01).ConclusionsRepeated and periodic PDT was technically feasible and safe and successfully maintained the therapeutic effects against obesity while eliminating the indwelling time and reducing ISD‐related complications in pigs.

show abstract

Experimental Gastric Non-Balloon Devices

Cited by 4 publications

References 18 publications

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Biomaterials in Gastroenterology: A Critical Overview

Repeated photodynamic therapy using a chlorin e6‐embedded device to prolong the therapeutic effects on obesity

Contact Info

Product

Resources

About